drugset / Trial / NCT02323685

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

NCT02323685

Phase 2 Completed 12 enrolled Prolong Pharmaceuticals
NaSingle-groupOpen-label

Summary

Safety and effect of SANGUINATE on patients DCI following SAH.

Timeline

Start
2014-12
Primary completion
2016-06
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject pegylated carboxyhemoglobin bovine Protein / enzyme biologic

Indications